International Journal of Medical Research & Health Sciences (IJMRHS)
ISSN: 2319-5886 Indexed in: ESCI (Thomson Reuters)

www.hxznw.com www.micaze.com www.bursaglobe.com www.enjoyantalya.com www.gzzzn.com pornofb.com pornstab.com xvideosxporn.com burdur escort bartın escort eskişehir escort izmir escort escort bursa üvey anne pornosu escort izmir

Comparison of the effectiveness of equal doses of short and long-acting erythrocyte stimulating agents for managing anemia in chronic kidney disease adult patients

Author(s):Abdulmalik Alkatheri, Abdelkareem Albekairy, Yousef Al-Rajhi, Shamylan Al-Harbi, Khalifah Alkhamees, Fayez F. Hejaili, Rami Bustami, Wesam Abdel-Razaq, Amjad M. Qandil and Mahmoud Mansour

Anemia is the most common side effect in patients with chronic kidney disease (CKD) mainly due to lower levels of erythropoietin (EPO) hormone. The aim of the present study is to compare the efficacy of equivalent doses of erythropoiesis stimulating agents (ESAs): short acting (Eprex®; Epoetin alfa) and long acting (Darbepoetin alfa: DA) in the treatment of anemia of CKD adult patients treated from September 2013 to January 2015. A total of fifty five patients were included; 22 patients were treated with Eprex®® (Epoetin alfa) and 33 patients received DA. Different blood indices were assessed in the initial 8 weeks. The equality of the doses was based on the conversion formula (1 μg of DA = 300 IU Eprex®). Treatment with lower dose of DA (0.64±0.07 μg/kg QW) induced a significant increase in hemoglobin (Hb) from week 4 through week 8, while red blood corpuscles (RBCs) and hematocrit (Hct) were significantly elevated in week 8. A significant increase in Hb and Hct were observed starting from week 2 through week 8 parallel with a significant rise in RBCs count, starting from week 3 through week 8 after treatment with DA (0.8±0.06 μg/kg QW), while a significant increment of Hb and Hct were noticed after treatment with DA (1.215±0.11 μg/kg QW) from week 3 to week 7. Administration of higher dose DA (1.37±0.22 μg/kg QW) led to a significant rise of RBCs in week 3, 6 and 7 while Hb and Hct in week 6 and 7. Treatment with equal doses of Eprex® (170.85±16.4 IU/kg and 238±25.9 IU/kg) induced only a mild increase in RBCs in week 7 and 6 respectively, while higher dose of Eprex® (413±40.8 IU/kg) elevated RBCs significantly at week 8 and Hct in week 6 and 8. Administration of DA QW is more effective than Eprex® QTIW in terms of target anemia parameters: RBCs, Hb and Hct during the first 8 weeks of administration.

Card image
Subscribe Now!
Scope Categories
  • Clinical Research
  • Epidemiology
  • Oncology
  • Biomedicine
  • Dentistry
  • Medical Education
  • Physiotherapy
  • Pulmonology
  • Nephrology
  • Gynaecology
  • Dermatology
  • Dermatoepidemiology
  • Otorhinolaryngology
  • Ophthalmology
  • Sexology
  • Osteology
  • Kinesiology
  • Neuroscience
  • Haematology
  • Psychology
  • Paediatrics
  • Angiology/Vascular Medicine
  • Critical care Medicine
  • Cardiology
  • Endocrinology
  • Gastroenterology
  • Infectious Diseases and Vaccinology
  • Hepatology
  • Geriatric Medicine
  • Bariatrics
  • Pharmacy and Nursing
  • Pharmacognosy and Phytochemistry
  • Radiobiology
  • Pharmacology
  • Toxicology
  • Clinical immunology
  • Clinical and Hospital Pharmacy
  • Cell Biology
  • Genomics and Proteomics
  • Pharmacogenomics
  • Bioinformatics and Biotechnology
  • Recommended Conferences

    International Conference on Haematology and Medical Oncology

    Edinburgh, Scotland

    Medical Summit and Expo on Healthcare and Medicine

    London, United Kingdom